Treating visceral pain via molecular targets on afferent neurons: Current and future

Chronic Abdominal and Visceral Pain: Theory and Practice

Volumn , Issue , 2006, Pages 245-269

  Holzer, Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36549055918     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (304)

1. Holzer P. Gastrointestinal pain in functional bowel disorders: sensory neurons as novel drug targets. Expert Opin Ther Targets 2004; 8:107-123.
2. Perry MJ, Lawson SN. Differences in expression of oligosaccharides, neuropeptides, carbonic anhy-drase and neurofilament in rat primary afferent neurons retrogradely labelled via skin, muscle or visceral nerves. Neuroscience 1998; 85:293-310.
3. Hornby PJ. Receptors and transmission in the brain-gut axis. II. Excitatory amino acid receptors in the brain-gut axis. Am J Physiol 2001; 280:G1055-G1060.
4. Gebhart GF. Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. IV. Visceral afferent contributions to the pathobiology of visceral pain. Am J Physiol 2000; 278: G834-G838.
5. Mayer EA, Collins SM. Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 2002; 122:2032-2048.
6. q/11 pathway. Proc Natl Acad Sci USA 2002; 99:14740-14745.
7. Lembo PMC, Grazzini E, Groblewski T, et al. Proenkephalin a gene products activate a new family of sensory neuron-specific GPCRs. Nat Neurosci 2002; 5:201-209.
8. Zylka MJ, Dong X, Southwell AL, Anderson DJ. Atypical expansion in mice of the sensory neuron-specific Mrg G protein-coupled receptor family. Proc Natl Acad Sci USA 2003; 100:10043-10048.
9. Shinohara T, Harada M, Ogi K, et al. Identification of a G protein-coupled receptor specifically responsive to beta-alanine. J Biol Chem 2004; 279:23559-23564.
10. Andrews PL, Sanger GJ. Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction. Curr Opin Pharmacol 2002; 2:650-656.
11. Gershon MD. Plasticity in serotonin control mechanisms in the gut. Curr Opin Pharmacol 2003; 3:600-607.
12. De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut 2004; 53:1520-1535.
13. Miwa J, Echizen H, Matsueda K, Umeda N. Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. Digestion 2001; 63:188-194.
14. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacoge-netics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123:425-432.
15. Linden DR, Chen JX, Gershon MD, Sharkey KA, Mawe GM. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol 2003; 285:G207-G216.
16. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126:1657-1664.
17. Yeo A, Boyd P, Lumsden S, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 2004; 53:1452-1458.
18. Kirkup AJ, Brunsden AM, Grundy D. Receptors and transmission in the brain-gut axis: potential for novel therapies. I. Receptors on visceral afferents. Am J Physiol 2001; 280:G787-G794.
19. 3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 2000; 46:474-480.
20. 4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17:577-585.
21. Yu S, Long JM, Mathis C, Nass PH, Lacy BE, Crowell MD. A 5-HT4 receptor partial agonist, tegaserod maleate, inhibits cortical and subcortical c-fos activation following noxious colorectal distension in the mouse. Neurogastroenterol Motil 2001; 13:445.
22. Schikowski A, Thewissen M, Mathis C, Ross HG, Enck P. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002; 14:221-227.
23. 2B receptor antagonist in vitro and in vivo. Br J Pharmacol 2004; 143:549-560.
24. Sugiuar T, Bielefeldt K, Gebhart GF. TRPV1 function in mouse colon sensory neurons is enhanced by metabotropic 5-hydroxytryptamine receptor activation. J Neurosci 2004; 24:9521-9530.
25. 7 receptors are involved in mediating 5-HT-induced activation of rat primary afferent neurons. Life Sci 2002; 71:2279-2289.
26. Wei J-Y, Wang YH. Effect of CCK pretreatment on the CCK sensitivity of rat polymodal gastric vagal afferents in vitro. Am J Physiol 2000; 279:E695-E706.
27. Moriarty P, Dimaline R, Thompson DG, Dockray GJ. Characterization of cholecystokinin-A and cholecystokinin-B receptors expressed by vagal afferent neurons. Neuroscience 1997; 79:905-913.
28. Sternini C, Wong H, Pham T, et al. Expression of cholecystokinin A receptors in neurons innervating the rat stomach and intestine. Gastroenterology 1999; 117:1136-1146.
29. Broberger C, Holmberg K, Shi TJ, Dockray G, Hokfelt T. Expression and regulation of cholecysto-kinin and cholecystokinin receptors in rat nodose and dorsal root ganglia. Brain Res 2001; 903: 128-140.
30. Patterson LM, Zheng H, Berthoud HR. Vagal afferents innervating the gastrointestinal tract and CCKA-receptor immunoreactivity. Anat Rec 2002; 266:10-20.
31. Fried M, Feinle C. The role of fat and cholecystokinin in functional dyspepsia. Gut 2002; 51(suppl 1): i54-i57.
32. Kellow JE, Phillips SF, Miller LJ, Zinsmeister AR. Dysmotility of the small intestine in irritable bowel syndrome. Gut 1988; 29:1236-1243.
33. Roberts-Thomson IC, Fettman MJ, Jonsson JR, Frewin DB. Responses to cholecystokinin octapeptide in patients with functional abdominal pain syndromes. J Gastroenterol Hepatol 1992; 7: 293-297.
34. Gay J, Fioramonti J, Garcia-Villar R, Bueno L. Enhanced intestinal motor response to cholecystokinin in post-Nippostrongylus brasiliensis-infected rats: modulation by CCK receptors and the vagus nerve. Neurogastroenterol Motil 2001; 13:155-162.
35. Leslie FC, Thompson DG, McLaughlin JT, Varro A, Dockray GJ, Mandal BK. Plasma cholecystoki-nin concentrations are elevated in acute upper gastrointestinal infections. Qart J Med 2003; 96: 870-871.
36. 1 receptors in colonic motor function. Br J Pharmacol 2004; 141:1275-1284.
37. Plourde V, Lembo T, Shui Z, et al. Effects of the somatostatin analogue octreotide on rectal afferent nerves in humans. Am J Physiol 1993; 265:G742-G751.
38. Bradette M, Delvaux M, Staumont G, Fioramonti J, Bueno L, Frexinos J. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994; 39:1171-1178.
39. Hasler WL, Soudah HC, Owyang C. Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. J Pharmacol Exp Ther 1994; 268:1206-1211.
40. Chey WD, Beydoun A, Roberts DJ, Hasler WL, Owyang C. Octreotide reduces perception of rectal electrical stimulation by spinal afferent pathway inhibition. Am J Physiol 1995; 269:G821-G826.
41. Mertz H, Walsh JH, Sytnik B, Mayer EA. The effect of octreotide on human gastric compliance and sensory perception. Neurogastroenterol Motil 1995; 7:175-185.
42. Foxx-Orenstein A, Camilleri M, Stephens D, Burton D. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut 2003; 52:1555-1561.
43. Schwetz I, Naliboff B, Munakata J, et al. Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19:123-131.
44. 2 receptor-mediated inhibition of mesenteric afferent nerves of the jejunum in the anesthetized rat. Gastroenterology 2001; 121:358-369.
45. Szolcsányi J, Bolcskei K, Szabo A, et al. Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia. Eur J Pharmacol 2004; 498:103-109.
46. Su X, Burton MB, Gebhart GF. Effects of octreotide on responses to colorectal distension in the rat. Gut 2001; 48:676-682.
47. Bley KR, Hunger JC, Eglen RM, Smith JAM. The role of EP receptors in hyperalgesia. Trends Pharmacol Sci 1998; 19:141-147.
48. 3 receptor knockout mice. Br J Pharmacol 2001; 133:438-444.
49. 2-induced cAMP production and sensitization of sensory neurons. J Biol Chem 2001; 276: 16083-16091.
50. 4) receptors in spinal nociceptive processing of input from the normal or inflamed knee joint. J Neurosci 2004; 24:642-651.
51. 2-induced nociceptive transmission in the rat spinal dorsal horn. Brain Res 2004; 1010:62-68.
52. Haupt W, Jiang W, Kreis ME, Grundy D. Prostaglandin EP receptor subtypes have distinct effects on jejunal afferent sensitivity in the rat. Gastroenterology 2000; 119:1580-1589.
53. Maubach KA, Grundy D. The role of prostaglandins in the bradykinin-induced activation of serosal afferents of the rat jejunum in vitro. J Physiol (London) 1999; 515:277-285.
54. 3 in endo-toxin-induced enhancement of pain perception. Biochem Pharmacol 2001; 62:157-160.
55. 2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology 2003; 124:18-25.
56. Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 2004; 3:845-852.
57. Heapy CG, Shaw JS, Farmer SC. Differential sensitivity of antinociceptive assays to the bradykinin antagonist Hoe 140. Br J Pharmacol 1993; 108:209-213.
58. Holzer-Petsche U, Brodacz B. Traction on the mesentery as a model of visceral nociception. Pain 1999; 80:319-328.
59. Guo ZL, Symons JD, Longhurst JC. Activation of visceral afferents by bradykinin and ischemia: independent roles of PKC and prostaglandins. Am J Physiol 1999; 276:H1884-H1891.
60. Brunsden AM, Grundy D. Sensitization of visceral afferents to bradykinin in rat jejunum in vitro. J Physiol (London) 1999; 521:517-527.
61. Premkumar LS, Ahern GP. Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000; 408:985-990.
62. 2 binding site as a determinant of capsaicin receptor sensitivity. Science 2003; 300:1284-1288.
63. Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997; 112:1714-1743.
64. Fischer HS, Zernig G, Hauser KF, Gerard C, Hersh LB, Saria A. Neutral endopeptidase knockout induces hyperalgesia in a model of visceral pain, an effect related to bradykinin and nitric oxide. J Mol Neurosci 2002; 18:129-134.
65. Julia V, Mezzasalma T, Bueno L. Influence of bradykinin in gastrointestinal disorders and visceral pain induced by acute or chronic inflammation in rats. Dig Dis Sci 1995; 40:1913-1921.
66. 2 receptors and mast cells in post intestinal infection-induced hypersensitivity to distension. Neurogastroenterol Motil 1998; 10:499-508.
67. Rosamilia A, Clements JA, Dwyer PL, Kende M, Campbell DJ. Activation of the kallikrein kinin system in interstitial cystitis. J Urol 1999; 162:129-134.
68. 2 receptors in normal and inflamed rat urinary bladder urothelium. J Physiol (London) 2005; 562:859-871.
69. Maggi CA, Santicioli P, Del Bianco E, Lecci A, Guliani S. Evidence for the involvement of bradyki-nin in chemically-evoked cystitis in anaesthetized rats. Naunyn-Schmiedeberg's Arch Pharmacol 1993; 347:432-437.
70. 2 receptor antagonists upon viscero-visceral hyper-reflexia in a rat model of visceral hyperalgesia. Pain 1998; 75:169-176.
71. Kawabata A. Gastrointestinal functions of proteinase-activated receptors. Life Sci 2003; 74:247-254.
72. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004; 84:579-621.
73. Vergnolle N. Modulation of visceral pain and inflammation by protease-activated receptors. Br J Pharmacol 2004; 141:1264-1274.
74. Kawao N, Ikeda H, Kitano T, et al. Modulation of capsaicin-evoked visceral pain and referred hyperalgesia by protease-activated receptors 1 and 2. J Pharmacol Sci 2004; 94:277-285.
75. Kirkup AJ, Jiang W, Bunnett NW, Grundy D. Stimulation of proteinase-activated receptor 2 excites jejunal afferent nerves in anaesthetised rats. J Physiol (London) 2003; 552:589-601.
76. Hoogerwerf WA, Zou L, Shenoy M, et al. The proteinase-activated receptor 2 is involved in nociception. J Neurosci 2001; 21:9036-9042.
77. Coelho AM, Vergnolle N, Guiard B, Fioramonti J, Bueno L. Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats. Gastroenterology 2002; 122:1035-1047.
78. Hoogerwerf WA, Shenoy M, Winston JH, Xiao SY, He Z, Pasricha PJ. Trypsin mediates nociception via the proteinase-activated receptor 2: a potentially novel role in pancreatic pain. Gastroenterology 2004; 127:883-891.
79. Amadesi S, Nie J, Vergnolle N, et al. Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J Neurosci 2004; 24:4300-4312.
80. Dai Y, Moriyama T, Higashi T, et al. Proteinase-activated receptor 2-mediated potentiation of transient receptor potential vanilloid subfamily 1 activity reveals a mechanism for proteinase-induced inflammatory pain. J Neurosci 2004; 24:4293-4299.
81. Cenac N, Garcia-Villar R, Ferrier L, et al. Proteinase-activated receptor-2-induced colonic inflammation in mice: possible involvement of afferent neurons, nitric oxide, and paracellular permeability. J Immunol 2003; 170:4296-4300.
82. Nguyen C, Coelho AM, Grady E, et al. Colitis induced by proteinase-activated receptor-2 agonists is mediated by a neurogenic mechanism. Can J Physiol Pharmacol 2003; 81:920-927.
83. Kim JA, Choi SC, Yun KJ, et al. Expression of protease-activated receptor 2 in ulcerative colitis. Inflamm Bowel Dis 2003; 9:224-229.
84. Vergnolle N, Cellars L, Mencarelli A, et al. A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest 2004; 114:1444-1456.
85. Gao C, Liu S, Hu HZ, Kim GY, Xia Y, Wood JD. Serine proteases excite myenteric neurons through protease-activated receptors in guinea pig small intestine. Gastroenterology 2002; 123:1554-1564.
86. Dunn PM, Zhong Y, Burnstock G. P2X receptors in peripheral neurons. Prog Neurobiol 2001; 65:107-134.
87. North RA. Molecular physiology of P2X receptors. Physiol Rev 2002; 82:1013-1067.
88. Zhong Y, Banning AS, Cockayne DA, Ford AP, Burnstock G, McMahon SB. Bladder and cutaneous sensory neurons of the rat express different functional P2X receptors. Neuroscience 2003; 120: 667-675.
89. Kirkup AJ, Booth CE, Chessell IP, Humphrey PP, Grundy D. Excitatory effect of P2X receptor activation on mesenteric afferent nerves in the anaesthetised rat. J Physiol (London) 1999; 520:551-563.
90. Burnstock G. Purine-mediated signalling in pain and visceral perception. Trends Pharmacol Sci 2001; 22:182-188.
91. 3 knock-out mice reveal a major sensory role for urothelially released ATP. J Neurosci 2001; 21:5670-5677.
92. Wynn G, Rong W, Xiang Z, Burnstock G. Purinergic mechanisms contribute to mechanosensory transduction in the rat colorectum. Gastroenterology 2003; 125:1398-1409.
93. Galligan JJ. Enteric P2X receptors as potential targets for drug treatment of the irritable bowel syndrome. Br J Pharmacol 2004; 141:1294-1302.
94. 3-deficient mice. Nature 2000; 407:1011-1015.
95. Knight GE, Bodin P, De Groat WC, Burnstock G. ATP is released from guinea pig ureter epithelium on distension. Am J Physiol 2002; 282:F281-F288.
96. Page AJ, O'Donnell TA, Blackshaw LA. P2X purinoceptor-induced sensitization of ferret vagal mechanoreceptors in oesophageal inflammation. J Physiol (London) 2000; 523:403-411.
97. Holzer P. Acid-sensitive ion channels in gastrointestinal function. Curr Opin Pharmacol 2003; 3:618-625.
98. Xu GY, Huang LY. Peripheral inflammation sensitizes P2X receptor-mediated responses in rat dorsal root ganglion neurons. J Neurosci 2002; 22:93-102.
99. 3 receptor expression in human bladder urothelium and changes in interstitial cystitis. BJU Int 2004; 93:1344-1348.
100. 3 is increased in human inflammatory bowel disease. Neurogastroenterol Motil 2001; 13:365-369.
101. 3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics. Pain 2002; 96:99-105.
102. 2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci USA 2002; 99:17179-17184.
103. Clapham DE. TRP channels as cellular sensors. Nature 2003; 426:517-524.
104. Patapoutian A, Peier AM, Story GM, Viswanath V. ThermoTRP channels and beyond: mechanisms of temperature sensation. Nat Rev Neurosci 2003; 4:529-539.
105. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389:816-824.
106. Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 1991; 43:143-201.
107. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 1999; 51:159-212.
108. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001; 24:487-517.
109. Hwang SW, Oh U. Hot channels in airways: pharmacology of the vanilloid receptor. Curr Opin Pharmacol 2002; 2:235-242.
110. Gunthorpe MJ, Benham CD, Randall A, Davis JB. The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol Sci 2002; 23:183-191.
111. Geppetti P, Trevisani M. Activation and sensitisation of the vanilloid receptor: role in gastrointestinal inflammation and function. Br J Pharmacol 2004; 141:1313-1320.
112. Holzer P. TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyper-algesia. Eur J Pharmacol 2004; 500:231-241.
113. Voets T, Droogmans G, Wissenbach U, Janssens A, Flockerzi V, Nilius B. The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels. Nature 2004; 430:748-754.
114. Birder LA, Nakamura Y, Kiss S, et al. Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci 2002; 5:856-860.
115. Patterson LM, Zheng H, Ward SM, Berthoud HR. Vanilloid receptor (VR1) expression in vagal afferent neurons innervating the gastrointestinal tract. Cell Tissue Res 2003; 311:277-287.
116. Ward SM, Bayguinov J, Won KJ, Grundy D, Berthoud HR. Distribution of the vanilloid receptor (VR1) in the gastrointestinal tract. J Comp Neurol 2003; 465:121-135.
117. Kadowaki M, Kuramoto H, Takaki M. Combined determination with functional and morphological studies of origin of nerve fibers expressing transient receptor potential vanilloid 1 in the myenteric plexus of the rat jejunum. Auton Neurosci 2004; 116:11-18.
118. Robinson DR, McNaughton PA, Evans ML, Hicks GA. Characterization of the primary spinal afferent innervation of the mouse colon using retrograde labelling. Neurogastroenterol Motil 2004; 16:113-124.
119. Schicho R, Florian W, Liebmann I, Holzer P, Lippe IT. Increased expression of TRPV1 receptor in dorsal root ganglia by acid insult of the rat gastric mucosa. Eur J Neurosci 2004; 19:1811-1818.
120. Horie S, Yamamoto H, Michael GJ, et al. Protective role of vanilloid receptor type 1 in HCl-induced gastric mucosal lesions in rats. Scand J Gastroenterol 2004; 39:303-312.
121. Avelino A, Cruz C, Nagy I, Cruz F. Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience 2002; 109:787-798.
122. Nozawa Y, Nishihara K, Yamamoto A, Nakano M, Ajioka H, Matsuura N. Distribution and characterization of vanilloid receptors in the rat stomach. Neurosci Lett 2001; 309:33-36.
123. Poonyachoti S, Kulkarni-Narla A, Brown DR. Chemical coding of neurons expressing delta- and kappa-opioid receptor and type I vanilloid receptor immunoreactivities in the porcine ileum. Cell Tissue Res 2002; 307:23-33.
124. Anavi-Goffer S, Coutts AA. Cellular distribution of vanilloid VR1 receptor immunoreactivity in the guinea-pig myenteric plexus. Eur J Pharmacol 2003; 458:61-71.
125. Chan CL, Facer P, Davis JB, et al. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 2003; 361:385-391.
126. Wang C, Hu HZ, Colton CK, Wood JD, Zhu MX. An alternative splicing product of the murine trpv1 gene dominant negatively modulates the activity of TRPV1 channels. J Biol Chem 2004; 279:37423-37430.
127. Su X, Wachtel RE, Gebhart GF. Capsaicin sensitivity and voltage-gated sodium currents in colon sensory neurons from rat dorsal root ganglia. Am J Physiol 1999; 277:G1180-G1188.
128. Blackshaw LA, Page AJ, Partosoedarso ER. Acute effects of capsaicin on gastrointestinal vagal afferents. Neuroscience 2000; 96:407-416.
129. Rong W, Hillsley K, Davis JB, Hicks G, Winchester WJ, Grundy D. Jejunal afferent nerve sensitivity in wild-type and TRPV1 knockout mice. J Physiol 2004; 560:867-881.
130. Drewes AM, Schipper KP, Dimcevski G, et al. Gut pain and hyperalgesia induced by capsaicin: a human experimental model. Pain 2003; 104:333-341.
131. Schmidt B, Hammer J, Holzer P, Hammer HF. Chemical nociception in the jejunum induced by capsaicin. Gut 2004; 53:1109-1116.
132. Laird JM, Martinez-Caro L, Garcia-Nicas E, Cervero F. A new model of visceral pain and referred hyperalgesia in the mouse. Pain 2001; 92:335-342.
133. 2A adrenoceptors contribute to feedback inhibition of capsaicin-induced hyperalgesia. Anesthesiology 2004; 101:185-190.
134. Reeh PW, Petho G. Nociceptor excitation by thermal sensitization-a hypothesis. Prog Brain Res 2000; 129:39-50.
135. Caterina MJ, Leffler A, Malmberg AB, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000; 288:306-313.
136. Davis JB, Gray J, Gunthorpe MJ, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000; 405:183-187.
137. Matthews PJ, Aziz Q, Facer P, Davis JB, Thompson DG, Anand P. Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus. Eur J Gastroenterol Hepatol 2004; 16:897-902.
138. Yiangou Y, Facer P, Dyer NH, et al. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet 2001; 357:1338-1339.
139. Brady CM, Apostolidis AN, Harper M, et al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 2004; 93:770-776.
140. Lamb K, Kang YM, Gebhart GF, Bielefeldt K. Gastric inflammation triggers hypersensitivity to acid in awake rats. Gastroenterology 2003; 125:1410-1418.
141. Lembeck F, Skofitsch G. Visceral pain reflex after pretreatment with capsaicin and morphine. Naunyn-Schmiedeberg's Arch Pharmacol 1982; 321:116-122.
142. Plourde V, St.-Pierre S, Quirion R. Calcitonin gene-related peptide in viscerosensitive response to colorectal distension in rats. Am J Physiol 1997; 273:G191-G196.
143. Delafoy L, Raymond F, Doherty AM, Eschalier A, Diop L. Role of nerve growth factor in the trinitrobenzene sulfonic acid-induced colonic hypersensitivity. Pain 2003; 105:489-497.
144. Bley KR. Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin Investig Drugs 2004; 13:1445-1456.
145. Cruz F. Mechanisms involved in new therapies for overactive bladder. Urology 2004; 63(suppl 1): 65-73.
146. Lysy J, Sistiery-Ittah M, Israelit Y, et al. Topical capsaicin - a novel and effective treatment for idio-pathic intractable pruritus ani: a randomised, placebo controlled, crossover study. Gut 2003; 52:1323-1326.
147. Bortolotti M, Coccia G, Grossi G, Miglioli M. The treatment of functional dyspepsia with red pepper. Aliment Pharmacol Ther 2002; 16:1075-1082.
148. Schmulson MJ, Valdovinos MA, Milke P. Chili pepper and rectal hyperalgesia in irritable bowel syndrome. Am J Gastroenterol 2003; 98:1214-1215.
149. Urban L, Campbell EA, Panesar M, et al. In vivo pharmacology of SDZ 249-665, a novel, non-pungent capsaicin analogue. Pain 2000; 89:65-74.
150. Jaggar SI, Scott HCF, James IF, Rice ASC. The capsaicin analogue SDZ 249-665 attenuates the hyper-reflexia and referred hyperalgesia associated with inflammation of the rat urinary bladder. Pain 2001; 89:229-235.
151. Bevan S, Hothi S, Hughes G, et al. Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. Br J Pharmacol 1992; 107:544-552.
152. McVey DC, Vigna SR. The capsaicin VR1 receptor mediates substance P release in toxin A-induced enteritis in rats. Peptides 2001; 22:1439-1446.
153. Kihara N, De La Fuente SG, Fujino K, Takahashi T, Pappas TN, Mantyh CR. Vanilloid receptor-1 containing primary sensory neurones mediate dextran sulphate sodium induced colitis in rats. Gut 2003; 52:713-719.
154. Kimball ES, Wallace NH, Schneider CR, D'Andrea MR, Hornby PJ. Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulphate sodium-induced colitis in mice. Neurogastroenterol Motil 2004; 16:811-818.
155. Holzer P. Neural emergency system in the stomach. Gastroenterology 1998; 114:823-839.
156. Holzer P. Vanilloid receptor TRRPV1: hot on the tongue and inflaming the colon. Neurogastroenterol Motil 2004; 16:697-699.
157. +-gated cation channels: neuronal acid sensors in the NaC/DEG family of ion channels. Curr Opin Neurobiol 1998; 8:418-424.
158. Kellenberger S, Schild L. Epithelial sodium channel/degenerin family of ion channels: a variety of functions for a shared structure. Physiol Rev 2002; 82:735-767.
159. Krishtal O. The ASICs: signaling molecules?. Modulators?. Trends Neurosci 2003; 26:477-483.
160. Alvarez de la Rosa D, Zhang P, Shao D, White F, Canessa CM. Functional implications of the localization and activity of acid-sensitive channels in rat peripheral nervous system. Proc Natl Acad Sci USA 2002; 99:2326-2331.
161. +-gated channels in mouse sensory neurons. Proc Natl Acad Sci USA 2002; 99:2338-2343.
162. Xie J, Prise MP, Berger AL, Welsh MJ. DRASIC contributes to pH-gated currents in large dorsal root ganglion sensory neurons by forming heteromultimeric channels. J Neurophysiol 2002; 87: 2835-2843.
163. + channels. J Biol Chem 2002; 277:2369-2372.
164. Price MP, Lewin GR, McIlwrath SL, et al. The mammalian sodium channel BNC1 is required for normal touch sensation. Nature 2000; 407:1007-1011.
165. Price MP, McIlwrath SL, Xie J, et al. The DRASIC cation channel contributes to the detection of cutaneous touch and acid stimuli in mice. Neuron 2001; 32:1071-1083.
166. Chen CC, Zimmer A, Sun WH, Hall J, Brownstein MJ, Zimmer A. A role for ASIC3 in the modulation of high-intensity pain stimuli. Proc Natl Acad Sci USA 2002; 99:8992-8997.
167. Page AJ, Brierley SM, Martin CM, et al. The ion channel ASIC1 contributes to visceral but not cutaneous mechanoreceptor function. Gastroenterology 2004; 127:1739-1747.
168. Yiangou Y, Facer P, Smith JA, et al. Increased acid-sensing ion channel ASIC-3 in inflamed human intestine. Eur J Gastroenterol Hepatol 2001; 13:891-896.
169. Mamet J, Baron A, Lazdunski M, Voilley N. Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. J Neurosci 2002; 22:10662-10670.
170. Goldstein SA, Bockenhauer D, O'Kelly I, Zilberberg N. Potassium leak channels and the KCNK family of two-P-domain subunits. Nat Rev Neurosci 2001; 2:175-184.
171. + channels. Trends Neurosci 2001; 24:339-346.
172. + channel family. J Biol Chem 2000; 275:17412-17419.
173. + channel TREK-1. EMBO J 2002; 21:2968-2976.
174. Ozaki N, Gebhart GF. Characterization of mechanosensitive splanchnic nerve afferent fibers innervating the rat stomach. Am J Physiol 2001; 281:G1449-G1459.
175. Su X, Wachtel RE, Gebhart GF. Mechanosensitive potassium channels in rat colon sensory neurons. J Neurophysiol 2000; 84:836-843.
176. Raybould HE, Gschossman JM, Ennes H, Lembo T, Mayer EA. Involvement of stretch-sensitive calcium flux in mechanical transduction in visceral afferents. J Auton Nerv Syst 1999; 75:1-6.
177. Suzuki M, Mizuno A, Kodaira K, Imai M. Impaired pressure sensation with mice lacking TRPV4. J Biol Chem 2003; 278:22664-22668.
178. Lai J, Porreca F, Hunter JC, Gold MS. Voltage-gated sodium channels and hyperalgesia. Annu Rev Pharmacol Toxicol 2004; 44:371-397.
179. Wood JN, Boorman JP, Okuse K, Baker MD. Voltage-gated sodium channels and pain pathways. J Neurobiol 2004; 61:55-71.
180. v1.9 (NaN) in nociceptive primary afferent neurons. J Neurosci 2002; 22:7425-7433.
181. + channel alpha subunit protein. J Physiol (London) 2003; 546:565-576.
182. v1.8 (SNS/PN3): expression and correlation with membrane properties in rat nociceptive primary afferent neurons. J Physiol (London) 2003; 550:739-752.
183. Bielefeldt K, Ozaki N, Gebhart GF. Mild gastritis alters voltage-sensitive sodium currents in gastric sensory neurons in rats. Gastroenterology 2002; 122:752-661.
184. Na in rat colonic sensory neurons. J Neurophysiol 2002; 88:1512-1522.
185. Moore BA, Stewart TM, Hill C, Vanner SJ. TNBS ileitis evokes hyperexcitability and changes in ionic membrane properties of nociceptive DRG neurons. Am J Physiol 2002; 282:G1045-G1051.
186. Stewart T, Beyak MJ, Vanner S. Ileitis modulates potassium and sodium currents in guinea pig dorsal root ganglia sensory neurons. J Physiol (London) 2003; 552:797-807.
187. + currents in mouse colonic dorsal root ganglia neurons and their role in colitis-induced hyperexcitability. Am J Physiol 2004; 287:G845-G855.
188. Bielefeldt K, Ozaki N, Gebhart GF. Experimental ulcers alter voltage-sensitive sodium currents in rat gastric sensory neurons. Gastroenterology 2002; 122:394-405.
189. Bielefeldt K, Ozaki N, Gebhart GF. Role of nerve growth factor in modulation of gastric afferent neurons in the rat. Am J Physiol 2003; 284:G499-G507.
190. v1.9 sodium current in mouse DRG neurons via G-proteins. Brain Res 2004; 1023:264-271.
191. v1.8 (PN3/SNS) in a rat model of visceral pain. J Neurosci 2001; 21:8690-8696.
192. v1.8 (SNS/PN3)-null mice. J Neurosci 2002; 22:8352-8356.
193. Ness TJ. Intravenous lidocaine inhibits visceral nociceptive reflexes and spinal neurons in the rat. Anesthesiology 2000; 92:1685-1691.
194. v1.8 peripheral nerve sodium channels by the local anesthetic lidocaine. Br J Pharmacol 2004; 142:576-584.
195. Su X, Joshi SK, Kardos S, Gebhart GF. Sodium channel blocking actions of the kappa-opioid receptor agonist U50,488 contribute to its visceral antinociceptive effects. J Neurophysiol 2002; 87: 1271-1279.
196. Bielefeldt K, Ozaki N, Whiteis C, Gebhart GF. Amitriptyline inhibits voltage-sensitive sodium currents in rat gastric sensory neurons. Dig Dis Sci 2002; 47:959-966.
197. Cervero F, Laird JM. Role of ion channels in mechanisms controlling gastrointestinal pain pathways. Curr Opin Pharmacol 2003; 3:608-612.
198. Ocana M, Cendan CM, Cobos EJ, Entrena JM, Baeyens JM. Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol 2004; 500:203-219.
199. Rasband MN, Park EW, Vanderah TW, Lai J, Porreca F, Trimmer JS. Distinct potassium channels on pain-sensing neurons. Proc Natl Acad Sci USA 2001; 98:13373-13378.
200. Dang K, Bielefeldt K, Gebhart GF. Gastric ulcers reduce A-type potassium currents in rat gastric sensory ganglion neurons. Am J Physiol 2004; 286:G573-G579.
201. + currents in neurons of the dorsal root ganglion of the adult rat. J Pharmacol Exp Ther 2004; 310:159-168.
202. Newton RA, Bingham S, Case PC, Sanger GJ, Lawson SN. Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta1 subunit following partial sciatic nerve injury. Mol Brain Res 2001; 95:1-8.
203. Sutton KG, Martin DJ, Pinnock RD, Lee K, Scott RH. Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. Br J Pharmacol 2002; 135:257-265.
204. Eutamene H, Coelho AM, Theodorou V, et al. Antinociceptive effect of pregabalin in septic shock-induced rectal hypersensitivity in rats. J Pharmacol Exp Ther 2000; 295:162-167.
205. Diop L, Raymond F, Fargeau H, Petoux F, Chovet M, Doherty AM. Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat. J Pharmacol Exp Ther 2002; 302:1013-1022.
206. Feng Y, Cui M, Willis WD. Gabapentin markedly reduces acetic acid-induced visceral nociception. Anesthesiology 2003; 98:729-733.
207. McGivern JG, McDonough SI. Voltage-gated calcium channels as targets for the treatment of chronic pain. Curr Drug Targets CNS Neurol Disord 2004; 3:457-478.
208. Horvath G, Brodacz B, Holzer-Petsche U. Role of calcium channels in the spinal transmission of nociceptive information from the mesentery. Pain 2001; 93:35-41.
209. Fundytus ME. Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs 2001; 15:29-58.
210. Carlton SM, Coggeshall RE. Inflammation-induced changes in peripheral glutamate receptor populations. Brain Res 1999; 820:63-70.
211. McRoberts JA, Coutinho SV, Marvizon JC, et al. Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats. Gastroenterology 2001; 120:1737-1748.
212. Bhave G, Karim F, Carlton SM, Gereau RW. Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat Neurosci 2001; 4:417-423.
213. Walker K, Reeve A, Bowes M, et al. mGlu5 receptors and nociceptive function. II. mGlu5 receptors functionally expressed on peripheral sensory neurons mediate inflammatory hyperalgesia. Neuropharmacology 2001; 40:10-19.
214. Carlton SM, Hargett GL, Coggeshall RE. Localization of metabotropic glutamate receptors 2/3 on primary afferent axons in the rat. Neuroscience 2001; 105:957-969.
215. Zhai QZ, Traub RJ. The NMDA receptor antagonist MK-801 attenuates c-Fos expression in the lum-bosacral spinal cord following repetitive noxious and non-noxious colorectal distention. Pain 1999; 83:321-329.
216. Kozlowski CM, Bountra C, Grundy D. The effect of fentanyl, DNQX and MK-801 on dorsal horn neurones responsive to colorectal distension in the anaesthetized rat. Neurogastroenterol Motil 2000; 12:239-247.
217. Coutinho SV, Urban MO, Gebhart GF. The role of CNS NMDA receptors and nitric oxide in visceral hyperalgesia. Eur J Pharmacol 2001; 429:319-325.
218. Coutinho SV, Meller ST, Gebhart GF. Intracolonic zymosan produces visceral hyperalgesia in the rat that is mediated by spinal NMDA and non-NMDA receptors. Brain Res 1996; 736:7-15.
219. Gaudreau GA, Plourde V. Involvement of N-methyl-D-aspartate (NMDA) receptors in a rat model of visceral hypersensitivity. Behav Brain Res 2004; 150:185-189.
220. Lu Y, Vera-Portocarrero LP, Westlund KN. Intrathecal coadministration of D-APV and morphine is maximally effective in a rat experimental pancreatitis model. Anesthesiology 2003; 98:734-740.
221. Rice AS, McMahon SB. Pre-emptive intrathecal administration of an NMDA receptor antagonist (AP-5) prevents hyper-reflexia in a model of persistent visceral pain. Pain 1994; 57:335-340.
222. Chen Y, Bacon G, Sher E, et al. Evaluation of the activity of a novel metabotropic glutamate receptor antagonist (+/-)-2-amino-2-(3-cis and trans-carboxycyclobutyl-3-(9-thioxanthyl)propionic acid) in the in vitro neonatal spinal cord and in an in vivo pain model. Neuroscience 2000; 95:787-793.
223. Bianchi R, Rezzani R, Borsani E, Rodella L. mGlu5 receptor antagonist decreases Fos expression in spinal neurons after noxious visceral stimulation. Brain Res 2003; 960:263-266.
224. Zhu CZ, Wilson SG, Mikusa JP, et al. Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol 2004; 506:107-118.
225. Fink-Jensen A, Judge ME, Hansen JB, et al. Inhibition of cisplatin-induced emesis in ferrets by the non-NMDA receptor antagonists NBQX and CNQX. Neurosci Lett 1992; 137:173-177.
226. Partosoedarso ER, Blackshaw LA. Roles of central glutamate, acetylcholine and CGRP receptors in gastrointestinal afferent inputs to vagal preganglionic neurones. Auton Neurosci 2000; 83:37-48.
227. Berthoud HR, Earle T, Zheng H, Patterson LM, Phifer C. Food-related gastrointestinal signals activate caudal brainstem neurons expressing both NMDA and AMPA receptors. Brain Res 2001; 915:143-154.
228. Sengupta JN, Petersen J, Peles S, Shaker R. Response properties of antral mechanosensitive afferent fibers and effects of ionotropic glutamate receptor antagonists. Neuroscience 2004; 125:711-723.
229. 2 receptors in the medullary transmission of vagal afferent input from the acid-threatened rat stomach. Pain 2001; 89:147-157.
230. Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Management 2000; 20:358-373.
231. Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 2001; 429:71-78.
232. Karim F, Bhave G, Gereau RW. Metabotropic glutamate receptors on peripheral sensory neuron terminals as targets for the development of novel analgesics. Mol Psychiatry 2001; 6:615-617.
233. Neugebauer V. Peripheral metabotropic glutamate receptors: fight the pain where it hurts. Trends Neurosci 2001; 24:550-552.
234. Kirchgessner AL. Glutamate in the enteric nervous system. Curr Opin Pharmacol 2001; 1:591-596.
235. Green T, Dockray GJ. Characterization of the peptidergic afferent innervation of the stomach in the rat, mouse, and guinea-pig. Neuroscience 1988; 25:181-193.
236. Sternini C. Enteric and visceral afferent CGRP neurons. Targets of innervation and differential expression patterns. Ann New York Acad Sci 1992; 657:170-186.
237. Friese N, Diop L, Chevalier E, Angel F, Riviere PJM, Dahl SG. Involvement of prostaglandins and CGRP-dependent sensory afferents in peritoneal irritation-induced visceral pain. Regul Pept 1997; 70:1-7.
238. Julia V, Bueno L. Tachykininergic mediation of viscerosensitive responses to acute inflammation in rats: role of CGRP. Am J Physiol 1997; 272:G141-G146.
239. Ghia JE, Crenner F, Metz-Boutigue MH, Aunis D, Angel F. The effect of a chromogranin A-derived peptide (CgA4-16) in the writhing nociceptive response induced by acetic acid in rats. Life Sci 2004; 75:1787-1799.
240. Gschossmann JM, Coutinho SV, Miller JC, et al. Involvement of spinal calcitonin gene-elated peptide in the development of acute visceral hyperalgesia in the rat. Neurogastroenterol Motil 2001; 13:229-236.
241. Olesen J, Diener HC, Husstedt IW, et al. BIBN 4096 BS clinical proof of concept study group. Calci-tonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350:1104-1110.
242. Lecci A, Valenti C, Maggi CA. Tachykinin receptor antagonists in irritable bowel syndrome. Curr Opin Investig Drugs 2002; 3:589-601.
243. Holzer P. Role of tachykinins in the gastrointestinal tract. In: Holzer P, ed. Tachykinins. Handbook of Experimental Pharmacology. 164. Vol. 164. Berlin: Springer, 2004:511-558.
244. 3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain. Br J Pharmacol 2004; 141:1303-1312.
245. Lee O-Y, Munakata J, Naliboff BD, Chang L, Mayer EA. A double blind parallel group pilot study of the effects of CJ-11,974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. Gastroenterology 2000; 118:A-846.
246. 1 receptor gene. Neuroscience 2000; 98:345-352.
247. Julia V, Morteau O, Bueno L. Involvement of neurokinin 1 and 2 receptors in viscerosensitive response to rectal distension in rats. Gastroenterology 1994; 107:94-102.
248. Julia V, Su X, Bueno L, Gebhart GF. Role of neurokinin 3 receptors on responses to colorectal distention in the rat: electrophysiological and behavioral studies. Gastroenterology 1999; 116:1124-1131.
249. 2 receptors in normal and altered rectal sensitivity in rats. Br J Pharmacol 2000; 129:193-199.
250. 2 receptors. Neuropharmacology 2001; 40:696-701.
251. 2 receptors in gastric barosensitivity and in experimental ileus in rats. Neurogastroenterol Motil 2001; 13:45-53.
252. Shafton AD, Bogeski G, Kitchener PD, Lewis VA, Sanger GJ, Furness JB. Effects of the peripherally acting NK3 receptor antagonist, SB-235375, on intestinal and somatic nociceptive responses and on intestinal motility in anaesthetized rats. Neurogastroenterol Motil 2004; 16:223-231.
253. 1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. J Pharmacol Exp Ther 2002; 300:925-931.
254. 1 receptors. Pain 2003; 102:227-234.
255. 1 receptor-mediated mechanisms regulate colonic hypersensitivity in the guinea pig. Pharmacol Biochem Behav 2003; 74:1005-1013.
256. Schwetz I, Bradesi S, McRoberts JA, et al. Delayed stress-induced colonic hypersensitivity in male Wistar rats: role of neurokinin-1 and corticotropin-releasing factor-1 receptors. Am J Physiol 2004; 286:G683-G691.
257. Holzer-Petsche U, Rordorf-Nikolic T. Central versus peripheral site of action of the tachykinin NK1-antagonist RP 67580 in inhibiting chemonociception. Br J Pharmacol 1995; 115:486-490.
258. McLean PG, Garcia-Villar R, Fioramonti J, Bueno L. Effects of tachykinin receptor antagonists on the rat jejunal distension pain response. Eur J Pharmacol 1998; 345:247-252.
259. 2 receptors. Eur J Pharmacol 1997; 337:279-282.
260. 3 receptors in the modulation of visceral hypersensitivity in the rat. Neurosci Lett 2003; 351:59-62.
261. Kamp EH, Beck DR, Gebhart GF. Combinations of neurokinin receptor antagonists reduce visceral hyperalgesia. J Pharmacol Exp Ther 2001; 299:105-113.
262. 1 receptor is upregulated after chronic bladder irritation. Pain 2001; 93:43-50.
263. Honore P, Kamp EH, Rogers SD, Gebhart GF, Mantyh PW. Activation of lamina I spinal cord neurons that express the substance P receptor in visceral nociception and hyperalgesia. J Pain 2002; 3:3-11.
264. 1 receptors following colon inflammation. Neuroscience 2003; 116:565-572.
265. Birder LA, Kiss S, de Groat WC, Lecci A, Maggi CA. Effect of nepadutant, a neurokinin 2 tachykinin receptor antagonist, on immediate-early gene expression after trinitrobenzenesulfonic acid-induced colitis in the rat. J Pharmacol Exp Ther 2003; 304:272-276.
266. Kishimoto S, Kobayashi H, Machino H, Tari A, Kajiyama G, Miyoshi A. High concentrations of substance P as a possible transmission of abdominal pain in rats with chemical induced ulcerative colitis. Biomed Res 1994; 15(suppl 2):133-140.
267. 3 receptors. Eur J Pharmacol 2001; 428:215-220.
268. 3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action. Neurogastroenterol Motil 2003; 15:363-369.
269. 1) antagonists. Trends Pharmacol Sci 1999; 20:485-490.
270. 1 receptor in nausea and emesis. In: Holzer P, ed. Tachykinins. Handbook of Experimental Pharmacology. 164. Vol. 164. Berlin: Springer, 2004:359-440.
271. Ji RR, Zhang Q, Law PY, Low HH, Elde R, Hokfelt T. Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. J Neurosci 1995; 15:8156-8166.
272. Minami M, Maekawa K, Yabuuchi K, Satoh M. Double in situ hybridization study on coexistence of mu-, delta- and kappa-opioid receptor mRNAs with preprotachykinin A mRNA in the rat dorsal root ganglia. Mol Brain Res 1995; 30:203-210.
273. Ozaki N, Sengupta JN, Gebhart GF. Differential effects of mu-, delta-, and kappa-opioid receptor agonists on mechanosensitive gastric vagal afferent fibers in the rat. J Neurophysiol 2000; 83:2209-2216.
274. Stein C, Schäfer M, Machelska H. Attacking pain at its source: new perspectives on opioids. Nat Med 2003; 9:1003-1008.
275. Riviere PJ. Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol 2004; 141:1331-1334.
276. Fürst S. Transmitters involved in antinociception in the spinal cord. Brain Res Bull 1999; 48:129-141.
277. 2-adrenoceptor agonist. CNS Drug Rev 2004; 10:117-126.
278. 2-adrenergic receptors in rat primary afferent neurones after peripheral nerve injury or inflammation. J Physiol (London) 1999; 515:533-542.
279. 2-Adrenergic receptors in human dorsal root ganglia. Anesthesiology 2000; 92:968-976.
280. Ono H, Mishima A, Ono S, Fukuda H, Vasko MR. Inhibitory effects of clonidine and tizanidine on release of substance P from slices of rat spinal cord and antagonism by alpha-adrenergic receptor antagonists. Neuropharmacology 1991; 30:585-589.
281. Ueda M, Oyama T, Kuraishi Y, Akaike A, Satoh M. Alpha2-adrenoceptor-mediated inhibition of capsaicin-evoked release of glutamate from rat spinal dorsal horn slices. Neurosci Lett 1995; 188:137-139.
282. 2a-adrenoceptor stimulation reduces capsaicin-induced glutamate release from spinal cord synaptosomes. J Pharmacol Exp Ther 2001; 299:939-944.
283. Pertovaara A, Kalmari J. Comparison of the visceral antinociceptive effects of spinally administered MPV-2426 (fadolmidine) and clonidine in the rat. Anesthesiology 2003; 98:189-194.
284. 2-adrenergic agents in humans. Gastroenterology 1999; 116:573-585.
285. 2 adrenergic modulation of colonic and rectal motor and sensory function. Aliment Pharmacol Ther 2000; 14:783-793.
286. Cannon RO, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994; 330:1411-1417.
287. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol 1996; 31:318-325.
288. 2-adrenoceptors play an integral role in the antinociceptive mechanism of action of antidepressant compounds?. Eur J Pharmacol 1999; 378:161-168.
289. Su X, Gebhart GF. Effects of tricyclic antidepressants on mechanosensitive pelvic nerve afferent fibers innervating the rat colon. Pain 1998; 76:105-114.
290. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63:569-611.
291. Hornby PJ, Prouty SM. Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol 2004; 141:1335-1345.
292. 1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 1999; 90:923-931.
293. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience 2000; 100:685-688.
294. 1 receptor antagonist SR141716A increases capsaicin-evoked release of substance P from the adult mouse spinal cord. Br J Pharmacol 2002; 135:21-24.
295. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 1999; 92:1171-1175.
296. Piomelli D, Giuffrida A, Calignano A, Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000; 21:218-224.
297. Szallasi A, Di Marzo V. New perspectives on enigmatic vanilloid receptors. Trends Neurosci 2000; 23:491-497.
298. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neu-rophysiological and neuroanatomical perspectives. Chem Phys Lipids 2002; 121:173-190.
299. Rice AS, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 2002; 66:243-256.
300. Coutts AA, Izzo AA. The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol 2004; 4:572-579.
301. Dinis P, Charrua A, Avelino A, et al. Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J Neurosci 2004; 24:11253-11263.
302. 2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76:189-199.
303. 1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001; 134:563-570.
304. Blackshaw LA, Gebhart GF. The pharmacology of gastrointestinal nociceptive pathways. Curr Opin Pharmacol 2002; 2:642-649.